Salvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease models

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Zhou, Jie ^a   Qu, Xiao Dong ^a   Li, Zhi Yun ^a   Wei Ji, ^a   Liu, Qi ^a   Ma, Yi Hui ^a   He, Jiao Jiang ^a  

^a LANZHOU GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; SALVIANOLIC ACID B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; 1 METHYL 4 PHENYLPYRIDINIUM; BENZOFURAN DERIVATIVE; CYTOKINE; GDNF PROTEIN, MOUSE; LIPOPOLYSACCHARIDE; NFE2L2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRADYKINESIA; CELL ACTIVATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE SILENCING; GLIA CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NERVE CELL CULTURE; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NRF2 GENE; PARKINSON DISEASE; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; ASTROCYTE; BIOLOGICAL MODEL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; MICROGLIA; PATHOLOGY;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ASTROCYTES; BENZOFURANS; CELLS, CULTURED; CYTOKINES; DOPAMINERGIC NEURONS; GENE EXPRESSION REGULATION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICROGLIA; MODELS, BIOLOGICAL; NF-E2-RELATED FACTOR 2; PARKINSON DISEASE;

EID: 84903761080     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101668     Document Type: Article

References (62)

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, et al. (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68: 384-386. (Pubitemid 46184217)
2. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909. (Pubitemid 37130207)
3. Lang AE, Lozano AM(1998) Parkinson's disease. First of two parts. N Engl J Med 339: 1044-1053. (Pubitemid 28457867)
4. Yacoubian TA, Standaert DG (2009) Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta 1792: 676-687.
5. Heneka MT, Rodriguez JJ, Verkhratsky A (2010) Neuroglia in neurodegeneration. Brain Res Rev 63: 189-211.
6. Gourine AV, Kasymov V, Marina N, Tang F, Figueiredo MF, et al. (2010) Astrocytes control breathing through pH-dependent release of ATP. Science 329: 571-575.
7. Wolosker H, Dumin E, Balan L, Foltyn VN (2008) D-amino acids in the brain: D-serine in neurotransmission and neurodegeneration. FEBS J 275: 3514-3526.
8. Long-Smith CM, Sullivan AM, Nolan YM (2009) The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 89: 277-287.
9. Kim YS, Joh TH (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 38: 333-347. (Pubitemid 44390511)
10. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, et al. (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102: 216-222. (Pubitemid 43194069)
11. Ossola B, Schendzielorz N, Chen SH, Bird GS, Tuominen RK, et al. (2011) Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology 61: 574-582.
12. Cao W, Guo XW, Zheng HZ, Li DP, Jia GB, et al. (2012) Current progress of research on pharmacologic actions of salvianolic acid B. Chin J Integr Med 18: 316-320.
13. Tang MK, Ren DC, Zhang JT, Du GH (2002) Effect of salvianolic acids from Radix Salviae miltiorrhizae on regional cerebral blood flow and platelet aggregation in rats. Phytomedicine 9: 405-409.
14. Zhao Y, Guo Y, Gu X (2011) Salvianolic Acid B, a potential chemopreventive agent, for head and neck squamous cell cancer. J Oncol 2011: 534548.
15. Wang ZS, Luo P, Dai SH, Liu ZB, Zheng XR, et al. (2013) Salvianolic acid B induces apoptosis in human glioma U87 cells through p38-mediated ROS generation. Cell Mol Neurobiol 33: 921-928.
16. Chen SC, Lin YL, Huang B, Wang DL, Cheng JJ (2011) Salvianolic acid B suppresses IFN-gamma-induced JAK/STAT1 activation in endothelial cells. Thromb Res 128: 560-564.
17. Chen T, Liu W, Chao X, Zhang L, Qu Y, et al. (2011) Salvianolic acid B attenuates brain damage and inflammation after traumatic brain injury in mice. Brain Res Bull 84: 163-168.
18. Tsai MK, Lin YL, Huang YT (2010) Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats. Toxicol Appl Pharmacol 242: 155-164.
19. Tian LL, Wang XJ, Sun YN, Li CR, Xing YL, et al. (2008) Salvianolic acid B, an antioxidant from Salvia miltiorrhiza, prevents 6-hydroxydopamine induced apoptosis in SH-SY5Y cells. Int J Biochem Cell Biol 40: 409-422.
20. Zeng G, Tang T, Wu HJ, You WH, Luo JK, et al. (2010) Salvianolic acid B protects SH-SY5Y neuroblastoma cells from 1-methyl-4-phenylpyridinium-induced apoptosis. Biol Pharm Bull 33: 1337-1342.
21. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, et al. (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81: 1285-1297. (Pubitemid 34809262)
22. Chen T, Yang YF, Luo P, Liu W, Dai SH, et al. (2013) Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson's disease. Cell Signal 25: 2863-2870.
23. Gao HM, Hong JS, Zhang W, Liu B (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22: 782-790. (Pubitemid 34141759)
24. Katagiri N, Chida S, Abe K, Nojima H, Kitabatake M, et al. (2010) Preventative effects of 1,3-dimethyl- and 1,3-dimethyl-N-propargyl-1,2,3,4- tetrahydroisoquinoline on MPTP-induced Parkinson's disease-like symptoms in mice. Brain Res 1321: 133-142.
25. Rojas P, Serrano-Garcia N, Medina-Campos ON, Pedraza-Chaverri J, Maldonado PD, et al. (2011) S-Allylcysteine, a garlic compound, protects against oxidative stress in 1-methyl-4-phenylpyridinium-induced parkinsonism in mice. J Nutr Biochem 22: 937-944.
26. Mythri RB, Harish G, Bharath MM (2012) Therapeutic potential of natural products in Parkinson's disease. Recent Pat Endocr Metab Immune Drug Discov 6: 181-200.
27. Di Stefano A, Sozio P, Cerasa LS, Iannitelli A (2011) L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment. Curr Pharm Des 17: 3482-3493.
28. Lipski J, Nistico R, Berretta N, Guatteo E, Bernardi G, et al. (2011) L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease? Prog Neurobiol 94: 389-407.
29. Marzatico F, Cafe C, Taborelli M, Benzi G (1993) Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas. Neurochem Res 18: 1101-1106. (Pubitemid 23309276)
30. Campos HC, da Rocha MD, Viegas FP, Nicastro PC, Fossaluzza PC, et al. (2011) The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson's disease. CNS Neurol Disord Drug Targets 10: 239-250.
31. Houghton PJ, Howes MJ (2005) Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neurosignals 14: 6-22. (Pubitemid 40868980)
32. Imanshahidi M, Hosseinzadeh H (2006) The pharmacological effects of Salvia species on the central nervous system. Phytother Res 20: 427-437. (Pubitemid 43953393)
33. Zhou L, Zuo Z, Chow MS (2005) Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45: 1345-1359. (Pubitemid 41643896)
34. Ho JH, Hong CY (2011) Salvianolic acids: small compounds with multiple mechanisms for cardiovascular protection. J Biomed Sci 18: 30.
35. Kopin IJ, Markey SP (1988) MPTP toxicity: implications for research in Parkinson's disease. Annu Rev Neurosci 11: 81-96. (Pubitemid 18081034)
36. Kopin IJ, Schoenberg DG (1988) MPTP in animal models of Parkinson's disease. Mt Sinai J Med 55: 43-49. (Pubitemid 18047089)
37. Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61: 1191-1206. (Pubitemid 23285075)
38. Deguil J, Jailloux D, Page G, Fauconneau B, Houeto JL, et al. (2007) Neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in MPP+-induced alteration of translational control in Neuro-2a neuroblastoma cells. J Neurosci Res 85: 2017-2025. (Pubitemid 47051490)
39. Kalivendi SV, Kotamraju S, Cunningham S, Shang T, Hillard CJ, et al. (2003) 1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. Biochem J 371: 151-164. (Pubitemid 36458089)
40. Halliday GM, Stevens CH (2011) Glia: initiators and progressors of pathology in Parkinson's disease. Mov Disord 26: 6-17.
41. Ciesielska A, Joniec I, Kurkowska-Jastrzebska I, Cudna A, Przybylkowski A, et al. (2009) The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease. Inflamm Res 58: 747-753.
42. Iannaccone S, Cerami C, Alessio M, Garibotto V, Panzacchi A, et al. (2013) In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat Disord 19: 47-52.
43. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, et al. (2003) Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 17: 500-502.
44. Marchetti B, Abbracchio MP (2005) To be or not to be (inflamed)-is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol Sci 26: 517-525. (Pubitemid 41338562)
45. Streit WJ (2002) Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40: 133-139.
46. Stanic D, Tripanichkul W, Drago J, Finkelstein DI, Horne MK (2004) Glial responses associated with dopaminergic striatal reinnervation following lesions of the rat substantia nigra. Brain Res 1023: 83-91. (Pubitemid 39195337)
47. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, et al. (1998) Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57: 1-9. (Pubitemid 28279554)
48. Sawada M, Imamura K, Nagatsu T (2006) Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl: 373-381. (Pubitemid 44622226)
49. Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 11: 999-1016. (Pubitemid 40331301)
50. Song H, Stevens CF, Gage FH (2002) Astroglia induce neurogenesis from adult neural stem cells. Nature 417: 39-44. (Pubitemid 34498810)
51. Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A (1999) Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97: 703-716. (Pubitemid 29278045)
52. Darlington CL (2005) Astrocytes as targets for neuroprotective drugs. Curr Opin Investig Drugs 6: 700-703.
53. Motohashi H, Yamamoto M (2004) Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 10: 549-557. (Pubitemid 39433824)
54. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, et al. (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86. (Pubitemid 29045117)
55. Clark J, Simon DK (2009) Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal 11: 509-528.
56. Dhakshinamoorthy S, Jaiswal AK (2001) Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H: quinone oxidoreductase1 gene. Oncogene 20: 3906-3917. (Pubitemid 32646201)
57. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, et al. (2007) Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66: 75-85. (Pubitemid 46066791)
58. Tufekci KU, Civi Bayin E, Genc S, Genc K (2011) The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease. Parkinsons Dis 2011: 314082.
59. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, et al. (2009) Nrf2- mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A 106: 2933-2938.
60. Min KJ, Yang MS, Kim SU, Jou I, Joe EH (2006) Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J Neurosci 26: 1880-1887. (Pubitemid 43237001)
61. Kumar H, Kim IS, More SV, Kim BW, Choi DK (2014) Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases. Nat Prod Rep 31: 109-139.
62. Zhang H, Liu YY, Jiang Q, Li KR, Zhao YX, et al. (2014) Salvianolic acid A protects RPE cells against oxidative stress through activation of Nrf2/HO-1 signaling. Free Radic Biol Med 69: 219-228.